ReviewCurrent allergy and asthma reports2013
Mast cell activation syndrome: a review.
Review in Current allergy and asthma reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Understanding Tryptase Physiology, Clinical Significance, and Diagnostic Applications: Where Do We Stand?Biomolecules · 2026Review
- SARS-CoV-2 or Vaccinal Spike Protein can Induce Mast Cell Activation Syndrome (MCAS).Infectious disorders drug targets · 2025Article
- Cardiac Geometry and Function in Patients with Reflex Syncope.Journal of clinical medicine · 2024Review
- A Cross-Sectional Study of Cardiovascular Autonomic Reactivity in Ehlers-Danlos Syndrome.Cureus · 2024Article
- [Diagnosis and treatment of Dunbar syndrome].Schmerz (Berlin, Germany) · 2024Review
- Evaluation of the relationship between mast cell activation and postural orthostatic tachycardia syndrome in children and adolescents.Northern clinics of Istanbul · 2024Article
- Prognostic factors for the long term outcome after surgical celiac artery decompression in MALS.Orphanet journal of rare diseases · 2023Article
- A fully human anti-c-Kit monoclonal antibody 2G4 inhibits proliferation and degranulation of human mast cells.Molecular and cellular biochemistry · 2023Article
- Temporal model for central sensitization: A hypothesis for mechanism and treatment using systemic manual therapy, a focused review.MethodsX · 2023Review
- Hereditary alpha-tryptasemia modifies clinical phenotypes among individuals with congenital hypermobility disorders.HGG advances · 2022Article
- Safe administration of chemotherapy in mast cell activation syndrome.Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners · 2021Article
- Mast Cell Biology at Molecular Level: a Comprehensive Review.Clinical reviews in allergy & immunology · 2020Review
- A cross-sectional study of nausea in functional abdominal pain: relation to mucosal mast cells and psychological functioning.BMC gastroenterology · 2020Article
- Histamine release from intestinal mast cells induced by staphylococcal enterotoxin A (SEA) evokes vomiting reflex in common marmoset.PLoS pathogens · 2019Article
- Mast Cell Activation Syndrome.Clinical reviews in allergy & immunology · 2018Review
- Mast cell inhibition as a therapeutic approach in fibrodysplasia ossificans progressiva (FOP).Bone · 2018Article
- Mastocytosis in Children.Current allergy and asthma reports · 2017Review
- Drug desensitization in 17-year-old male with Mast Cell Activation Syndrome, pneumonia, and antibiotic hypersensitivities.AME case reports · 2017Article
- Sevoflurane ameliorates intestinal ischemia-reperfusion-induced lung injury by inhibiting the synergistic action between mast cell activation and oxidative stress.Molecular medicine reports · 2015Article
- The immunological contribution to heterotopic ossification disorders.Current osteoporosis reports · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mast cell activation syndrome (MCAS) is a condition with signs and symptoms involving the skin, gastrointestinal, cardiovascular, respiratory, and neurologic systems. It can be classified into primary, secondary, and idiopathic. Earlier proposed criteria for the diagnosis of MCAS included episodic symptoms consistent with mast cell mediator release affecting two or more organ systems with urticaria, angioedema, flushing, nausea, vomiting, diarrhea, abdominal cramping, hypotensive syncope or near syncope, tachycardia, wheezing, conjunctival injection, pruritus, and nasal stuffiness. Other criteria included a decrease in the frequency, severity, or resolution of symptoms with anti-mediator therapy including H(1) and H(2)histamine receptor antagonists, anti-leukotrienes, or mast cell stabilizers. Laboratory data that support the diagnosis include an increase of a validated urinary or serum marker of mast cell activation (MCA), namely the documentation of an increase of the marker above the patient's baseline value during symptomatic periods on more than two occasions, or baseline serum tryptase levels that are persistently above 15 ng/ml, or documentation of an increase of the tryptase level above baseline value on one occasion. Less specific assays are 24-h urine histamine metabolites, PGD(2) (Prostaglandin D(2)) or its metabolite, 11-β-prostaglandin F(2) alpha. A recent global definition, criteria, and classification include typical clinical symptoms, a substantial transient increase in serum total tryptase level or an increase in other mast cell derived mediators, such as histamine or PGD2 or their urinary metabolites, and a response of clinical symptoms to agents that attenuate the production or activities of mast cell mediators.
Indexed as
Identifiers
23179866What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.